Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model-Reference-Cited by-同舟云学术

Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model

Published:2020-09-25 Issue:2 Volume:17 Page:271-292
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Chen Xu‐Qiao¹,Salehi Ahmad²,Pearn Matthew L.³⁴,Overk Cassia¹,Nguyen Phuong D.¹,Kleschevnikov Alexander M.¹,Maccecchini Maria⁵,Mobley William C.¹

Affiliation:

1. Department of Neurosciences University of California San Diego La Jolla California USA

2. Department of Psychiatry & Behavioral Sciences Stanford Medical School Palo Alto California USA

3. Department of Anesthesiology University of California San Diego, School of Medicine La Jolla California USA

4. V.A. San Diego Healthcare System San Diego California USA

5. Annovis Bio Inc. Berwyn Pennsylvania USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12185

Reference150 articles.

1. Inflammation as a central mechanism in Alzheimer's disease

2. The amyloid hypothesis of Alzheimer's disease at 25 years

3. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage

4. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

5. An overview on the clinical development of tau‐based therapeutics;Medina M;Int. J. Mol. Sci,2018

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A superior near infrared fluorescent probe for revealing the relationship between peroxynitrite and Alzheimer's disease;Sensors and Actuators B: Chemical;2024-09

2. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease;Alzheimer's Research & Therapy;2024-07-05

3. APP dyshomeostasis in the pathogenesis of Alzheimer’s disease: implications for current drug targets;Alzheimer's Research & Therapy;2024-06-29

4. Comparative Analysis of Posiphen Pharmacokinetics across Different Species—Similar Absorption and Metabolism in Mouse, Rat, Dog and Human;Biomolecules;2024-05-15

5. γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down Syndrome;Annals of Neurology;2024-05-15